PI3K, AKT, and dual PI3K/mTOR inhibitors enhance FOXO3 nuclear localisation in breast cancer cells which is implicated in both sensitivity and feedback mediated resistance to pathway inhibition14,15. This evidence concerns the gene FOXO3 and breast carcinoma.